嘉必优(688089) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥117,020,437.16, representing a year-on-year increase of 33.34%[5] - Net profit attributable to shareholders was ¥24,312,520.44, reflecting a significant increase of 69.93% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,851,734.56, up 158.16% year-on-year[5] - Basic and diluted earnings per share were both ¥0.14, an increase of 55.56% from the previous year[5] - Total operating revenue for Q1 2024 reached ¥117,020,437.16, a 33.3% increase from ¥87,762,301.30 in Q1 2023[19] - Net profit for Q1 2024 was ¥23,674,695.14, representing an increase of 74.9% compared to ¥13,529,876.56 in Q1 2023[20] - Earnings per share for Q1 2024 were ¥0.14, compared to ¥0.09 in Q1 2023, reflecting a 55.6% increase[21] - The company reported a total comprehensive income of ¥23,674,014.90 for Q1 2024, compared to ¥13,529,876.56 in Q1 2023[21] Research and Development - The total R&D expenditure amounted to ¥10,446,443.25, which is 38.97% higher than the previous year[6] - R&D expenses accounted for 8.93% of total revenue, an increase of 0.36 percentage points year-on-year[6] - Research and development expenses for Q1 2024 totaled ¥10,446,443.25, a 39.5% increase from ¥7,517,071.87 in Q1 2023[20] - Research and development expenses increased to CNY 9,025,774.41, up from CNY 6,578,632.54 in Q1 2023, indicating a focus on innovation[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,617,239,179.46, a slight increase of 0.36% from the end of the previous year[6] - The company's total current assets as of March 31, 2024, amount to ¥695,345,201.26, a decrease from ¥708,743,774.48 at the end of 2023[15] - The total non-current assets increased to ¥921,893,978.20 from ¥902,748,612.84[16] - The total assets of the company as of March 31, 2024, are ¥1,617,239,179.46, slightly up from ¥1,611,492,387.32[16] - Current liabilities decreased to ¥95,050,876.62 from ¥112,198,399.38[16] - The total liabilities as of Q1 2024 were ¥99,674,221.83, down from ¥117,601,444.59 in the previous year[17] - The total liabilities decreased to CNY 158,833,723.59 from CNY 170,821,594.43, reflecting improved financial health[26] Cash Flow - The net cash flow from operating activities was ¥43,386,600.15, with no applicable year-on-year comparison[5] - Cash flow from operating activities in Q1 2024 was ¥147,121,472.17, slightly up from ¥144,447,146.59 in Q1 2023[22] - The net cash flow from operating activities was CNY 43,386,600.15, a significant recovery from a negative cash flow of CNY -5,286,511.48 in the same period last year[23] - Cash flow from operating activities generated a net amount of CNY 42,205,401.61 in Q1 2024, a significant increase from CNY 872,345.76 in Q1 2023[30] - The company reported a decrease in cash flow from investing activities, with a net outflow of CNY 85,399,536.33 in Q1 2024 compared to CNY 111,127,175.72 in Q1 2023[30] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,022[11] - The largest shareholder, Wuhan Xiwang Biological Engineering Co., Ltd., holds 74,340,000 shares, accounting for 44.17% of total shares[11] - Total equity attributable to shareholders increased to ¥1,500,664,353.42 in Q1 2024 from ¥1,476,352,513.22 in Q1 2023[17] - The company's total equity increased to CNY 1,528,747,766.13 from CNY 1,503,874,425.62, indicating growth in shareholder value[27] Other Financial Metrics - The weighted average return on equity was 1.62%, an increase of 0.62 percentage points compared to the previous year[5] - The company reported a government subsidy of ¥1,432,170.94, which is included in the non-recurring gains and losses[7] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending[12] - The company experienced a decrease in accounts receivable, which amounted to CNY 263,495,029.59, compared to CNY 231,636,845.67 at the end of 2023[25] - The company reported a significant reduction in other receivables, down to ¥10,785,002.29 from ¥29,245,718.32[15] - The company's cash and cash equivalents decreased to ¥191,772,952.79 from ¥239,677,461.72[15] - The company's cash and cash equivalents decreased by CNY 47,904,508.93 in Q1 2024, compared to a decrease of CNY 109,715,597.21 in Q1 2023[23] - The impact of exchange rate fluctuations on cash and cash equivalents was a positive CNY 236,433.84 in Q1 2024, compared to a negative impact of CNY 878,223.15 in Q1 2023[32]